New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
mosunetuzumab-axgb, Lunsumio
Synonyms :
mosunetuzumab
Class :
Anti-neoplastic, B-cell lymphoma inhibitors
Brand Name :
mosunetuzumab-axgb, Lunsumio
Synonyms :
mosunetuzumab
Class :
Anti-neoplastic, B-cell lymphoma inhibitors
Dosage Forms & StrengthsÂ
Injectable solutionÂ
1mg/mlÂ
30mg/30mlÂ
21-day cycle Day 1 Cycle 1: 1mg intravenous for 4 hours Day 8 Cycle 1: 2mg intravenous for 4 hours Day 1 Cycle 2: 60mg intravenous for 2 hours Day 15 Cycle 2: 60mg intravenous for 4 hours Cycle 3 and the following cycles Day 1: 30mg IV for 2 hours Restarting therapy 1mg administered last dose (Day 1 cycle 1) Week 1 and 2: Administer 2mg >2 week TO <6 weeks: administer 2 mg, then use 60 mg 2mg administered last dose (Day 8 cycle 1) Week 1 and 2: Administer 60mg >2 weeks: administer 1 mg, then use 2 mg >6 weeks: administer 1 mg and 2mg, then use 60 mg 60mg administered last dose (Day 15 cycle 1) Week 1 to <6 weeks: Administer 60mg >6 weeks: administer 1 mg and 2mg, then use 60 mg, followed by 30mg 60mg administered last dose (Day 1 cycle 2) Week 3 to <6 weeks: Administer 30mg >6 weeks: administer 1 mg and 2mg, then use 30 mg, followed by 30mg 30mg administered last dose (Cycle 3 and following cycles) Week 3 to <6 weeks: Administer 30mg >6 weeks: administer 1 mg on day 1 and 2mg on day 8, then use 30 mg on day 15, followed by 30mg on day 1 in the remaining cycles
Dosage Forms & StrengthsÂ
Safety and efficacy not establishedÂ
Refer adult dosingÂ
Frequency defined:Â Â
>10%Â
All gradesÂ
Decreased phosphateÂ
Decreased WBCÂ
Decreased plateletsÂ
FatigueÂ
RashÂ
Increased gamma-glutamyl transferaseÂ
Decreased potassiumÂ
Increased ALTÂ
Musculoskeletal painÂ
Increased uric acidÂ
Peripheral Neuropathy Â
DiarrheaÂ
Dry skinÂ
ChillsÂ
ArthralgiaÂ
Decreased lymphocyte countÂ
Decreased hemoglobinÂ
Decreased neutrophilsÂ
Increased glucoseÂ
PyrexiaÂ
CoughÂ
PruritisÂ
EdemaÂ
Upper respiratory tract infectionsÂ
Grades 3 and 4Â
Decreased phosphateÂ
Increased glucoseÂ
Decreased WBCÂ
Decreased lymphocyte countÂ
Increased glucoseÂ
Increased uric acidÂ
Decreased hemoglobinÂ
1-10%Â
All gradesÂ
Skin exfoliationÂ
Urinary tract infectionsÂ
Grades 3 and 4Â
Decreased plateletsÂ
Increased ALTÂ
RashÂ
PyrexiaÂ
ChillsÂ
Musculoskeletal painÂ
Abdominal painÂ
Increased GGTÂ
Decreased potassiumÂ
Increased ASTÂ Â
Upper respiratory tract infectionsÂ
EdemaÂ
Peripheral neuropathyÂ
DyspneaÂ
Urinary tract infectionsÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: mosunetuzumabÂ
Pronounced: (moe sun” e tooz’ ue mab)Â
Why do we use mosunetuzumab?Â
It is used to treat relapsed follicular lymphomaÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
